KDR and breast cancer: This regulatory crosstalk, known as the “γδ T cell–IL17A–neutrophil axis” drives immunosuppression even to the point of conferring resistance to high-dose anti-VEGFR2 (vascular endothelial growth factor receptor 2) breast cancer therapy [118].